FENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARK™ Read more about FENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARK™
Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update Read more about Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update Read more about Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update
Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update Read more about Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
Fennec Announces Issuance of U.S. Patent for PEDMARK™ Read more about Fennec Announces Issuance of U.S. Patent for PEDMARK™
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences Read more about Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors Read more about Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
Fennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update Read more about Fennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
